This could play an important role in fine‐tuning MMP9 activity in vivo as MMP9 is dysregulated in tumours with reduced COSMC levels, thereby contributing to the protease's unwanted and detrimental pro‐tumorigenic activities (Kessenbrock et al., 2010). Here, MMP9 is linked to neoplasm.